This week’s roundup captures the accelerating pace of innovation across the global biotech and pharmaceutical landscape. From Hansa Biopharma’s landmark Phase 3 trial success in kidney transplantation to DaltonTx’s £4 million seed raise for AI-driven drug discovery, the sector is brimming with breakthroughs. Xeltis, Poolbeg Pharma, and Heidelberg Pharma are all advancing important trials, while […]
Biotech investors like to think that their actions benefit society, by bringing to the market new drugs that save lives and spare people illness. And often they do. In many cases, only by them risking their capital, is great good done. Think of the early investors in BioNTech or Moderna, for instance. Without them, mRNA […]
AMS announced its Interim results for the six months ended 30 June 2025 This week Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announced its unaudited interim results for the six months ended 30 June 2025. Group revenue increased by 63% to £110.8 million and by 66% at constant currency […]
The big buzz around AI in healthcare is the potential it holds to identify and even create new drugs. “AI drug discovery” is the great new hope. And – despite critics awkwardly pointing out that no AI-generated drugs have yet been approved by any regulator, and vanishing few appear to be close to that finishing […]
AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]
